These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26109589)

  • 1. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome.
    Khan R; Lopes RD; Neely ML; Stevens SR; Harrington RA; Diaz R; Cools F; Jansky P; Montalescot G; Atar D; Lopez-Sendon J; Flather M; Liaw D; Wallentin L; Alexander JH; Goodman SG;
    Heart; 2015 Sep; 101(18):1475-84. PubMed ID: 26109589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban with antiplatelet therapy after acute coronary syndrome.
    Alexander JH; Lopes RD; James S; Kilaru R; He Y; Mohan P; Bhatt DL; Goodman S; Verheugt FW; Flather M; Huber K; Liaw D; Husted SE; Lopez-Sendon J; De Caterina R; Jansky P; Darius H; Vinereanu D; Cornel JH; Cools F; Atar D; Leiva-Pons JL; Keltai M; Ogawa H; Pais P; Parkhomenko A; Ruzyllo W; Diaz R; White H; Ruda M; Geraldes M; Lawrence J; Harrington RA; Wallentin L;
    N Engl J Med; 2011 Aug; 365(8):699-708. PubMed ID: 21780946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
    Sharma A; Hagström E; Wojdyla DM; Neely ML; Harrington RA; Wallentin L; Alexander JH; Goodman SG; Lopes RD;
    Am Heart J; 2019 Sep; 215():106-113. PubMed ID: 31310855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial.
    Hess CN; James S; Lopes RD; Wojdyla DM; Neely ML; Liaw D; Hagstrom E; Bhatt DL; Husted S; Goodman SG; Lewis BS; Verheugt FWA; De Caterina R; Ogawa H; Wallentin L; Alexander JH
    J Am Coll Cardiol; 2015 Aug; 66(7):777-787. PubMed ID: 26271059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J).
    Ogawa H; Goto S; Matsuzaki M; Hiro S; Shima D;
    Circ J; 2013; 77(9):2341-8. PubMed ID: 23748920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Sherwood MW; Lopes RD; Sun JL; Liaw D; Harrington RA; Wallentin L; Laskowitz DT; James SK; Goodman SG; Darius H; Lewis BS; Gibson CM; Pieper KS; Alexander JH
    Am Heart J; 2018 Mar; 197():1-8. PubMed ID: 29447769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.
    Jin J; Zhuo X; Xiao M; Jiang Z; Chen L; Devi Shamloll Y
    Medicine (Baltimore); 2021 Mar; 100(12):e25185. PubMed ID: 33761699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
    Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
    Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.
    Cornel JH; Lopes RD; James S; Stevens SR; Neely ML; Liaw D; Miller J; Mohan P; Amerena J; Raev D; Huo Y; Urina-Triana M; Gallegos Cazorla A; Vinereanu D; Fridrich V; Harrington RA; Wallentin L; Alexander JH;
    Am Heart J; 2015 Apr; 169(4):531-8. PubMed ID: 25819860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
    Yasaka M; Umeyama M; Kataoka H; Inoue H
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention.
    Gumprecht J; Domek M; Lip GYH
    Expert Opin Drug Saf; 2019 Dec; 18(12):1119-1125. PubMed ID: 31580164
    [No Abstract]   [Full Text] [Related]  

  • 17. Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial).
    Alkhalfan F; Nafee T; Yee MK; Chi G; Kalayci A; Plotnikov A; Braunwald E; Gibson CM
    Am J Cardiol; 2020 Mar; 125(5):661-669. PubMed ID: 31898965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.
    Widimsky P; Motovska Z; Bolognese L; Dudek D; Hamm C; Tanguay JF; Ten Berg J; Brown E; LeNarz L; Miller DL; Montalescot G;
    Heart; 2015 Aug; 101(15):1219-24. PubMed ID: 26060122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
    Goldstein S; Bates ER; Bhatt DL; Cao C; Holmes D; Kupfer S; Martinez F; Spaeder J; Weitz JI; Ye Z; Zannad F;
    Thromb Haemost; 2014 Jun; 111(6):1141-52. PubMed ID: 24671450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
    Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.